CANBRIDGE-B

1228
1.6701.76% ( -0.030 )
Delay Closed: Nov 16, 16:08:00

Profile

About

CANBRIDGE-B
CANBRIDGE-B
01228.HK

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy (ERT) for the treatment of Hunter syndrome; and Livmarli, an oral, minimally-absorbed, reversible ileal bile acid transporter inhibitor for the treatment of alagille syndrome and progressive familial intrahepatic cholestasis. It also develops CAN106, an anti-C5 mAb for paroxysmal nocturnal hemoglobinuria; and CAN103, a recombinant human ERT for the treatment of gaucher disease. In addition, the company develops CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody for X-linked hypophosphatemia; CAN104, a recombinant human ERT GLA for fabry disease; CAN105, a bispecific antibody for the treatment of hemophilia A; and CAN204 to treat Duchenne muscular dystrophy.

Profile

Company Name
CANbridge Pharmaceuticals Inc.
Market
SEHK
Founded
Industry
--
Fiscal Year End
December 31

Related Securities

Industry

Management